RedHill Biopharma (RDHL) Capital Expenditures (2012 - 2022)
RedHill Biopharma's (RDHL) quarterly Capital Expenditures came in at -$22000.0 in Q3 2022, down 4.76% year-on-year from -$23100.0 in Q3 2021, and up 86.5% on a QoQ basis from -$163000.0 in Q2 2022.
RedHill Biopharma (RDHL) Capital Expenditures (2012 - 2022) Analysis & Trends
RedHill Biopharma (RDHL) has 11 years of Capital Expenditures data on file, last reported at -$22000.0 in Q3 2022.
- On a quarterly basis, Capital Expenditures fell 4.76% year-over-year to -$22000.0 in Q3 2022; TTM through Dec 2022 was -$198000.0, a 72.17% decrease from a year earlier, with the FY2025 full-year figure at -$5000.0, up 44.44% from the prior year.
- Capital Expenditures for Q3 2022 stood at -$22000.0, up from -$163000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for RDHL reached as high as -$1000.0 in Q3 2019 and fell as low as -$242000.0 in Q1 2020.
- Historically, Capital Expenditures has averaged -$51631.6 across 5 years, with a median of -$20000.0 in 2020.
- Across the five-year window, Capital Expenditures surged 98.04% in 2018 and plunged 16500.0% in 2020, its largest moves.
- Year by year, Capital Expenditures stood at -$5000.0 in 2018, then slumped by 560.0% to -$33000.0 in 2019, then tumbled by 48.48% to -$49000.0 in 2020, then soared by 93.88% to -$3000.0 in 2021, then sank by 633.33% to -$22000.0 in 2022.
- Per Business Quant data, the three most recent Capital Expenditures figures were -$22000.0 in Q3 2022, -$163000.0 in Q2 2022, and -$13000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | RedHill Biopharma | 640,064.98 | 640,064.98 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -22,000.00 |
| Sep 30, 2022 | -22,000.00 |
| Jun 30, 2022 | -163,000.00 |
| Jun 30, 2022 | -163,000.00 |
| Mar 31, 2022 | -13,000.00 |
| Mar 31, 2022 | -13,000.00 |
| Dec 31, 2021 | -3,000.00 |
| Dec 31, 2021 | -3,000.00 |
| Sep 30, 2021 | -21,000.00 |
| Sep 30, 2021 | -21,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Mar 31, 2021 | -88,000.00 |
| Mar 31, 2021 | -88,000.00 |
| Dec 31, 2020 | -49,000.00 |
| Dec 31, 2020 | -49,000.00 |
| Sep 30, 2020 | -166,000.00 |
| Sep 30, 2020 | -166,000.00 |
| Jun 30, 2020 | -20,000.00 |
| Jun 30, 2020 | -20,000.00 |